BRPI0515649A - processo para preparação de composições de anticorpos altamente concentradas e processo para concentrar proteìnas - Google Patents
processo para preparação de composições de anticorpos altamente concentradas e processo para concentrar proteìnasInfo
- Publication number
- BRPI0515649A BRPI0515649A BRPI0515649-1A BRPI0515649A BRPI0515649A BR PI0515649 A BRPI0515649 A BR PI0515649A BR PI0515649 A BRPI0515649 A BR PI0515649A BR PI0515649 A BRPI0515649 A BR PI0515649A
- Authority
- BR
- Brazil
- Prior art keywords
- highly concentrated
- concentrated antibody
- antibody compositions
- preparing highly
- concentrating proteins
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 238000000108 ultra-filtration Methods 0.000 abstract 2
- 239000012141 concentrate Substances 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
- B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/16—Feed pretreatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/16—Flow or flux control
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
"PROCESSO PARA PREPARAçãO DE COMPOSIçõES DE ANTICORPOS ALTAMENTE CONCENTRADAS E PROCESSO PARA CONCENTRAR PROTEINAS". A presente divulgação fornece um processo para concentrar proteínas incluindo ultrafiltração, diafiltração e uma segunda seqüência ultrafiltração, em temperaturas elevadas, tais como aproximadamente acima de 30<198>C. A divulgação inclui também um processo para preparar composições altamente concentradas de anticorpo e produtos de anticorpo altamente concentrados.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60909204P | 2004-09-09 | 2004-09-09 | |
US60/609,092 | 2004-09-09 | ||
US11/220,362 US20060051347A1 (en) | 2004-09-09 | 2005-09-06 | Process for concentration of antibodies and therapeutic products thereof |
US11/220,362 | 2005-09-06 | ||
PCT/US2005/031844 WO2006031560A2 (en) | 2004-09-09 | 2005-09-08 | Process for concentration of antibodies and therapeutic products thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0515649A true BRPI0515649A (pt) | 2008-07-29 |
BRPI0515649B1 BRPI0515649B1 (pt) | 2021-10-13 |
BRPI0515649B8 BRPI0515649B8 (pt) | 2021-11-03 |
Family
ID=35996499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515649A BRPI0515649B8 (pt) | 2004-09-09 | 2005-09-08 | Processo para preparação de composições de anticorpo monoclonal altamente concentradas |
Country Status (33)
Country | Link |
---|---|
US (6) | US20060051347A1 (pt) |
EP (5) | EP2292636B9 (pt) |
JP (2) | JP5210633B2 (pt) |
KR (2) | KR20070109975A (pt) |
CN (3) | CN104961797B (pt) |
AR (1) | AR050641A1 (pt) |
AU (1) | AU2005285243C1 (pt) |
BR (1) | BRPI0515649B8 (pt) |
CA (1) | CA2577317C (pt) |
DK (5) | DK1786830T3 (pt) |
EC (1) | ECSP077282A (pt) |
ES (4) | ES2528541T3 (pt) |
FI (4) | FI4104859T3 (pt) |
GT (1) | GT200500254A (pt) |
HK (2) | HK1101249A1 (pt) |
HU (2) | HUE061899T2 (pt) |
IL (2) | IL181372A (pt) |
LT (4) | LT3805248T (pt) |
MA (1) | MA28991B1 (pt) |
MX (2) | MX342788B (pt) |
MY (2) | MY162525A (pt) |
NO (1) | NO333660B1 (pt) |
NZ (1) | NZ553239A (pt) |
PE (1) | PE20060816A1 (pt) |
PL (5) | PL4104859T3 (pt) |
PT (5) | PT4104859T (pt) |
RU (1) | RU2390524C2 (pt) |
SG (1) | SG177161A1 (pt) |
SI (5) | SI4104859T1 (pt) |
TN (1) | TNSN07069A1 (pt) |
TW (1) | TWI372630B (pt) |
WO (1) | WO2006031560A2 (pt) |
ZA (1) | ZA200701626B (pt) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US6875432B2 (en) * | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
PL1610820T5 (pl) | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
EP1713904B1 (en) | 2004-01-30 | 2016-06-29 | Shire Pharmaceuticals Ireland Limited | Production and purification of recombinant arylsulfatase a |
WO2005112885A2 (en) | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
PT1765294E (pt) | 2004-05-12 | 2008-12-30 | Baxter Healthcare Sa | Microesferas de ácido nucleico, sua produção e entrega |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
US20070246406A1 (en) * | 2006-03-31 | 2007-10-25 | Dibel Kevin R | Tangential flow filtration apparatuses, systems, and processes for the separation of compounds |
PL2628746T3 (pl) | 2006-04-04 | 2019-07-31 | Chiesi Farmaceutici S.P.A. | Sposób zatężania polipeptydu |
BRPI0809209A2 (pt) | 2007-03-29 | 2014-09-02 | Abbott Lab | Anticorpos il-12 anti-humanos cristalinos |
ES2401820T3 (es) | 2007-07-17 | 2013-04-24 | F. Hoffmann - La Roche Ag | Filtración de flujo tangencial variable |
CN101874040A (zh) * | 2007-11-29 | 2010-10-27 | 弗·哈夫曼-拉罗切有限公司 | 免疫球蛋白聚集体 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
EP2271382B1 (en) | 2008-04-15 | 2013-03-13 | Grifols Therapeutics Inc. | Two-stage ultrafiltration/diafiltration |
KR101645957B1 (ko) * | 2008-05-15 | 2016-08-05 | 더블유. 헬스 엘.피. | 분비 면역글로블린이 풍부한 우유 분획 제조방법 |
CA2744510A1 (en) * | 2008-12-09 | 2010-06-17 | F.Hoffmann-La Roche Ag | Method for obtaining an excipient-free antibody solution |
WO2010090864A2 (en) * | 2009-01-21 | 2010-08-12 | Smartflow Technologies, Inc. | Optimization of separation for viscous suspensions |
RU2011140498A (ru) * | 2009-03-06 | 2013-04-20 | Дженентек, Инк. | Препарат антител |
ES2733346T3 (es) * | 2009-03-24 | 2019-11-28 | Wyeth Llc | Evaporación por membrana para generar medicamentos proteicos altamente concentrados |
TWI445714B (zh) * | 2009-05-27 | 2014-07-21 | Baxter Int | 產製用於皮下使用之高濃度免疫球蛋白製備物之方法 |
ES2582581T3 (es) | 2009-09-29 | 2016-09-13 | F. Hoffmann-La Roche Ag | Ajuste prefiltración de solutos tampón para la preparación de inmunoglobulinas a alta concentración |
JP5458183B2 (ja) | 2009-10-01 | 2014-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | 多段階最終濾過方法 |
US9241897B2 (en) | 2010-02-04 | 2016-01-26 | Csl Behring Ag | Immunoglobulin preparation |
KR101807894B1 (ko) | 2010-03-01 | 2017-12-12 | 바이엘 헬스케어 엘엘씨 | 조직 인자 경로 억제제 (tfpi)에 대한 최적화된 모노클로날 항체 |
WO2013009686A2 (en) | 2011-07-08 | 2013-01-17 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase a |
CN103889555B (zh) * | 2011-09-01 | 2018-10-26 | 中外制药株式会社 | 通过超滤制备包含高度浓缩的抗体的组合物的方法 |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
CN104955479A (zh) * | 2012-12-28 | 2015-09-30 | 诺和诺德股份有限公司 | 高温死端抗体过滤 |
WO2014110246A1 (en) | 2013-01-09 | 2014-07-17 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase a |
DE102013001628A1 (de) | 2013-01-30 | 2014-07-31 | Fresenius Medical Care Deutschland Gmbh | Verfahren zur Bereitstellung eines Konzentrats |
EP4218991A1 (en) | 2014-05-13 | 2023-08-02 | Amgen Inc. | Process control systems and methods for use with filters and filtration processes |
EP4144434B1 (en) * | 2014-06-16 | 2024-04-17 | EMD Millipore Corporation | Single-pass filtration systems and processes |
WO2015195453A2 (en) * | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
EP2957335B1 (en) * | 2014-06-16 | 2020-05-27 | EMD Millipore Corporation | Single-pass filtration systems and processes |
US10207225B2 (en) * | 2014-06-16 | 2019-02-19 | Emd Millipore Corporation | Single-pass filtration systems and processes |
CN115463546A (zh) | 2014-06-25 | 2022-12-13 | Emd 密理博公司 | 过滤器元件、切向流过滤系统、产生进料筛网的方法 |
US10195550B2 (en) | 2014-08-29 | 2019-02-05 | Emd Millipore Corporation | Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
SG11201508665QA (en) | 2014-08-29 | 2016-03-30 | Emd Millipore Corp | Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate |
EA038462B1 (ru) | 2014-10-23 | 2021-08-31 | Эмджен Инк. | Снижение вязкости фармацевтических составов |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
EP3352790A1 (en) * | 2015-09-22 | 2018-08-01 | Pfizer Inc | Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method |
MX2019001859A (es) * | 2016-08-16 | 2019-08-29 | Genzyme Corp | Metodos de procesamiento de un fluido que incluye una proteina terapeutica recombinante y uso de los mismos. |
KR102457855B1 (ko) | 2016-08-17 | 2022-10-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 생체 분자를 함유하는 고농축 액상 제형의 제조 방법 |
JP6884858B2 (ja) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | 医薬製剤及びその製造方法 |
JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
CN107952280A (zh) * | 2017-11-28 | 2018-04-24 | 安徽东方帝维生物制品股份有限公司 | 一种兽用疫苗无菌超滤浓缩装置及方法 |
WO2019132418A1 (ko) * | 2017-12-27 | 2019-07-04 | ㈜셀트리온 | 투석 여과 방법 |
JP7465215B2 (ja) * | 2018-04-12 | 2024-04-10 | アムジェン インコーポレイテッド | 安定なタンパク質組成物を製造する方法 |
TWI846694B (zh) * | 2018-05-04 | 2024-07-01 | 美商健臻公司 | 具有過濾系統的灌注式生物反應器 |
US20210308265A1 (en) * | 2018-08-10 | 2021-10-07 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
US12103949B2 (en) | 2018-08-14 | 2024-10-01 | Bristol-Myers Squibb Company | Protein recovery |
TW202043253A (zh) * | 2019-01-28 | 2020-12-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
WO2021018978A1 (en) * | 2019-07-31 | 2021-02-04 | Catalent U.K. Swindon Zydis Limited | Density flow meter for pharmaceutical formulation dosing |
CN111018968B (zh) * | 2019-12-16 | 2021-07-27 | 兴盟生物医药(苏州)有限公司 | 一种通过超滤浓缩制备高浓度抗体制剂的方法 |
JP7338527B2 (ja) * | 2020-03-19 | 2023-09-05 | 東レ株式会社 | 体液検体中のアレルゲン特異的IgE抗体の検出方法 |
CN111944046B (zh) * | 2020-08-28 | 2021-04-09 | 江苏荃信生物医药有限公司 | 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法 |
KR20230080460A (ko) * | 2020-10-05 | 2023-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질을 농축시키는 방법 |
CN116507403A (zh) | 2020-11-23 | 2023-07-28 | Abec公司 | 过滤系统、部件和方法 |
CN114014929B (zh) * | 2021-11-04 | 2022-07-19 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法 |
WO2023164631A1 (en) | 2022-02-25 | 2023-08-31 | Amgen Inc. | Methods of preparing high concentration liquid drug substances |
CN115261193A (zh) * | 2022-05-31 | 2022-11-01 | 利穗科技(苏州)有限公司 | 一种生物制品浓缩系统及其工艺 |
WO2024012364A1 (en) * | 2022-07-12 | 2024-01-18 | Beigene Switzerland Gmbh | Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df) |
US12030959B1 (en) | 2023-07-05 | 2024-07-09 | Genentech, Inc. | Anti-IgE antibody therapy for multiple food allergies |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5625616B2 (pt) | 1973-10-08 | 1981-06-13 | ||
FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
ZA847349B (en) | 1983-10-05 | 1985-04-24 | Solco Basel Ag | Process for the preparation of a biologically active extract |
US4786501A (en) | 1985-07-15 | 1988-11-22 | International Minerals & Chemical Corp. | Cylindrical implants for the controlled release of growth hormones |
US4756696A (en) | 1985-12-06 | 1988-07-12 | Amp Incorporated | Solder joint inspection feature for surface mount connectors |
GB8628104D0 (en) * | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
JPS6485829A (en) | 1987-09-29 | 1989-03-30 | Aisin Aw Co | Transmission for four-wheel drive vehicle |
JPH01268646A (ja) | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
US4897465A (en) | 1988-10-12 | 1990-01-30 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US5177194A (en) * | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
NL9001650A (nl) | 1990-07-19 | 1992-02-17 | Ver Coop Melkind | Werkwijze voor de bereiding van een melkeiwit-isolaat. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
JP2907603B2 (ja) * | 1991-09-09 | 1999-06-21 | 雪印乳業株式会社 | 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品 |
US6270757B1 (en) | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5707678A (en) | 1995-04-12 | 1998-01-13 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CN100360184C (zh) * | 1995-07-27 | 2008-01-09 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
AU4589397A (en) * | 1997-09-22 | 1999-04-12 | Sepragen Corporation | Sequential separation of whey proteins and formulations thereof |
RU2140287C1 (ru) | 1998-08-25 | 1999-10-27 | Государственное унитарное предприятие "Иммунопрепарат" | Способ получения альбумина |
AU6405899A (en) | 1998-10-26 | 2000-05-15 | Galagen, Inc. | Soy and immunoglobulin compositions |
WO2001003515A1 (en) | 1999-07-07 | 2001-01-18 | New Zealand Co-Operative Dairy Company Limited | Method of obtaining protein isolates and concentrates from colostrum |
ES2644275T3 (es) * | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
US6875432B2 (en) * | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
WO2003042344A2 (en) * | 2001-11-13 | 2003-05-22 | Genentech, Inc. | Apo2 ligand/trail formulations |
WO2004001007A2 (en) * | 2002-06-21 | 2003-12-31 | Idec Pharmaceuticals Corporation | Buffered formulations for concentrating antibodies and methods of use thereof |
EP1596667B1 (en) * | 2002-11-01 | 2009-01-21 | Bayer HealthCare LLC | Process for the concentration of proteins |
GB0229444D0 (en) | 2002-12-18 | 2003-01-22 | Royal Free Hampstead Nhs Trust | Diagnostic method and assay kit |
AU2003261387A1 (en) * | 2003-02-24 | 2004-09-17 | Gtc Biotherapeutics, Inc. | Methods of tangential flow filtration and an apparatus therefore |
PL1610820T5 (pl) | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
KR20070009995A (ko) | 2004-01-30 | 2007-01-19 | 수오멘 푸나이넨 리스티 베리팔베루 | 바이러스 안전성 면역글로불린을 제조하는 방법 |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JP6044754B2 (ja) | 2012-01-19 | 2016-12-14 | 株式会社ジェイテクト | クラッチプレートおよびその製造方法 |
-
2005
- 2005-09-06 US US11/220,362 patent/US20060051347A1/en not_active Abandoned
- 2005-09-07 MY MYPI20054224A patent/MY162525A/en unknown
- 2005-09-07 MY MYPI20104600 patent/MY150549A/en unknown
- 2005-09-07 TW TW094130719A patent/TWI372630B/zh active
- 2005-09-08 FI FIEP22178156.0T patent/FI4104859T3/fi active
- 2005-09-08 EP EP10009914.2A patent/EP2292636B9/en active Active
- 2005-09-08 PL PL22178156.0T patent/PL4104859T3/pl unknown
- 2005-09-08 ES ES05806393.4T patent/ES2528541T3/es active Active
- 2005-09-08 CN CN201510468312.XA patent/CN104961797B/zh active Active
- 2005-09-08 SI SI200532319T patent/SI4104859T1/sl unknown
- 2005-09-08 KR KR1020077007862A patent/KR20070109975A/ko not_active Application Discontinuation
- 2005-09-08 SI SI200531932T patent/SI1786830T1/sl unknown
- 2005-09-08 EP EP20200642.5A patent/EP3805248B1/en active Active
- 2005-09-08 PL PL20200642.5T patent/PL3805248T3/pl unknown
- 2005-09-08 DK DK05806393.4T patent/DK1786830T3/en active
- 2005-09-08 PL PL10009914.2T patent/PL2292636T3/pl unknown
- 2005-09-08 MX MX2012011125A patent/MX342788B/es unknown
- 2005-09-08 CN CN200580038351.0A patent/CN101056885B/zh active Active
- 2005-09-08 FI FIEP20200642.5T patent/FI3805248T3/fi active
- 2005-09-08 LT LTEP20200642.5T patent/LT3805248T/lt unknown
- 2005-09-08 NZ NZ553239A patent/NZ553239A/en unknown
- 2005-09-08 PT PT221781560T patent/PT4104859T/pt unknown
- 2005-09-08 KR KR1020127030933A patent/KR101528970B1/ko active IP Right Review Request
- 2005-09-08 ES ES22178117T patent/ES2975166T3/es active Active
- 2005-09-08 DK DK10009914.2T patent/DK2292636T3/da active
- 2005-09-08 PT PT100099142T patent/PT2292636T/pt unknown
- 2005-09-08 ES ES20200642T patent/ES2942574T3/es active Active
- 2005-09-08 HU HUE20200642A patent/HUE061899T2/hu unknown
- 2005-09-08 PT PT221781172T patent/PT4108259T/pt unknown
- 2005-09-08 DK DK20200642.5T patent/DK3805248T5/da active
- 2005-09-08 EP EP05806393.4A patent/EP1786830B1/en not_active Revoked
- 2005-09-08 ES ES10009914T patent/ES2968070T3/es active Active
- 2005-09-08 LT LTEP22178156.0T patent/LT4104859T/lt unknown
- 2005-09-08 PT PT58063934T patent/PT1786830E/pt unknown
- 2005-09-08 SI SI200532316T patent/SI2292636T1/sl unknown
- 2005-09-08 BR BRPI0515649A patent/BRPI0515649B8/pt active IP Right Grant
- 2005-09-08 PL PL22178117.2T patent/PL4108259T3/pl unknown
- 2005-09-08 LT LTEP22178117.2T patent/LT4108259T/lt unknown
- 2005-09-08 HU HUE10009914A patent/HUE065025T2/hu unknown
- 2005-09-08 ZA ZA200701626A patent/ZA200701626B/xx unknown
- 2005-09-08 DK DK22178117.2T patent/DK4108259T3/da active
- 2005-09-08 DK DK22178156.0T patent/DK4104859T3/da active
- 2005-09-08 EP EP22178156.0A patent/EP4104859B1/en active Active
- 2005-09-08 FI FIEP10009914.2T patent/FI2292636T3/fi active
- 2005-09-08 CN CN2012103764183A patent/CN102911268A/zh active Pending
- 2005-09-08 SI SI200532312T patent/SI3805248T1/sl unknown
- 2005-09-08 SG SG2011088622A patent/SG177161A1/en unknown
- 2005-09-08 RU RU2007110534/13A patent/RU2390524C2/ru active
- 2005-09-08 LT LTEP10009914.2T patent/LT2292636T/lt unknown
- 2005-09-08 SI SI200532317T patent/SI4108259T1/sl unknown
- 2005-09-08 WO PCT/US2005/031844 patent/WO2006031560A2/en active Application Filing
- 2005-09-08 FI FIEP22178117.2T patent/FI4108259T3/fi active
- 2005-09-08 JP JP2007531302A patent/JP5210633B2/ja active Active
- 2005-09-08 PL PL05806393T patent/PL1786830T3/pl unknown
- 2005-09-08 CA CA2577317A patent/CA2577317C/en active Active
- 2005-09-08 EP EP22178117.2A patent/EP4108259B1/en active Active
- 2005-09-08 PT PT202006425T patent/PT3805248T/pt unknown
- 2005-09-08 AU AU2005285243A patent/AU2005285243C1/en active Active
- 2005-09-08 MX MX2007002812A patent/MX2007002812A/es not_active Application Discontinuation
- 2005-09-09 AR ARP050103779A patent/AR050641A1/es active IP Right Grant
- 2005-09-09 GT GT200500254A patent/GT200500254A/es unknown
- 2005-09-09 PE PE2005001049A patent/PE20060816A1/es active IP Right Grant
-
2006
- 2006-09-29 US US11/537,577 patent/US20070237762A1/en not_active Abandoned
-
2007
- 2007-02-15 IL IL181372A patent/IL181372A/en active IP Right Grant
- 2007-02-23 TN TNP2007000069A patent/TNSN07069A1/en unknown
- 2007-02-28 EC EC2007007282A patent/ECSP077282A/es unknown
- 2007-03-16 NO NO20071432A patent/NO333660B1/no unknown
- 2007-04-06 MA MA29809A patent/MA28991B1/fr unknown
- 2007-06-27 HK HK07106910.7A patent/HK1101249A1/xx not_active IP Right Cessation
-
2009
- 2009-02-19 US US12/389,140 patent/US20090214522A1/en not_active Abandoned
-
2011
- 2011-11-24 JP JP2011256451A patent/JP5426641B2/ja active Active
- 2011-12-08 IL IL216851A patent/IL216851A0/en unknown
-
2014
- 2014-04-21 US US14/257,907 patent/US10370456B2/en active Active
-
2016
- 2016-04-05 HK HK16103797.1A patent/HK1215869A1/zh unknown
-
2020
- 2020-09-10 US US17/017,465 patent/US20210095050A1/en active Pending
-
2022
- 2022-11-01 US US17/978,913 patent/US11767370B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515649A (pt) | processo para preparação de composições de anticorpos altamente concentradas e processo para concentrar proteìnas | |
ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
AR057614A1 (es) | Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas | |
BRPI0508610A (pt) | derivados de aminoácidos | |
PE20090711A1 (es) | Region constante de anticuerpo mutante | |
BRPI0815395A2 (pt) | Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição. | |
BR112012012460A2 (pt) | "método de liofilização, composições e kits". | |
DK1893587T3 (da) | Fremgangsmåde til fremstilling af dihydroquinazoliner | |
CY1109722T1 (el) | Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole | |
BRPI0809821A2 (pt) | "composição de proteína hidrolisada, processo para a preparação de uma composição de proteína hidrolisada e produto alimentício" | |
NZ584893A (en) | PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF | |
CL2008003794A1 (es) | Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular. | |
BR112014004828A2 (pt) | método para preparação de uma composição compreendendo anticorpos altamente concentrados por ultrafiltração | |
WO2006116181A3 (en) | Regulatory t cell mediator proteins and uses thereof | |
DE602005020185D1 (de) | Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4henprodukte für dieses verfahren | |
DK1726215T3 (da) | Fremgangsmåde til fremstilling af soja og mælkebaserede præparater med et höjt samlet proteinindhold | |
WO2013102211A3 (en) | Stabilized antiviral fusion helices | |
EP4374913A3 (en) | Novel human serum albumin mutant | |
MX2009007572A (es) | Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y. | |
BRPI0410861A (pt) | métodos e composições para a produção de aminoácidos | |
EA200701852A1 (ru) | Производные аминокислот | |
WO2008024919A8 (en) | Interferon antagonists, antibodies thereto, and associated methods of use | |
TW200740729A (en) | Methods for preparing glutamic acid derivatives | |
TR200400639T4 (tr) | Donmaya-karşı proteinler, bunların üretimleri ve kullanımları | |
ATE528278T1 (de) | Herstellung von 2-(1,3-dimethylbutyl)anilin und anderen verzweigten, alkylsubstituierten anilinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2649, QUANTO AO ENDERECO DO TITULAR |